RFA 5 Announcement
The Accelerating Clinical Trials (ACT) Consortium recently held a competition to bring high-impact randomized controlled trials to Canada that were initiated and are led by a non-Canadian country. One of the key objectives of the ACT Consortium is to expand Canadian participation in international trials – this funding opportunity is working towards this goal by […]
Group Selected to Run Pan-Canadian Single Research Ethics Board Review Process
International review panel selects CanReview to set up, initiate, and conduct a pan-Canadian single REB review and approval process with strict timelines. The Accelerating Clinical Trials consortium was funded in 2022 in the wake of the COVID pandemic to help facilitate the conduct of clinical trials in Canada. One of the main administrative slowdowns in […]
Canadian Biotech Opportunity
Click here for a full summary of the ACT October Meeting In preparation for the Third ACT Consortium Meeting, we are seeking Canadian biotechnology companies to connect with ACT Canada Researchers. Companies will have the opportunity to pitch their company to a variety of ACT members through presentations and/or exhibit tables in our conference rooms […]
New Pan-Canadian Data and Sample Transfer Agreement
New pan-Canadian data and sample transfer agreement a game-changer for clinical research “We’ve built a high-speed legal highway for researchers to use to share their data and samples.” Francais Research organizations across Canada are encouraged to sign onto the new governing Data and Samples Sharing Agreement (gDSSA), a game-changing approach that will help get clinical […]
Upcoming Webinars
For more information about upcoming webinars, please see the ACT Education page!
ACT-AEC First Annual Meeting
At the ACT-AEC First Annual Meeting, ACT-AEC invited 48 Canadian biotechnology companies to present their work to members of the consortium. ACT-AEC is proud to share the experiences of these companies in connecting with ACT-AEC’s consortium partners. To connect with ACT-AEC, contact us.
